Expert workgroup releases recommendations on the use of blood biomarkers in AD

Blood biomarkers (BBMs) for Alzheimer’s disease (AD) may revolutionize the diagnosis of AD in the future, but they are not yet ready for widespread use in the clinic, according to a global expert workgroup.

The workgroup’s recommendations were published online and presented at AAIC 2022. The cover the use of biomarkers such as plasma measures of Aβ42/Aβ40, phosphorylated tau, and neurofilament light chain (NfL).